Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P D Lamy

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The Journal of Infectious Diseases|December 8, 1998
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitroM D Miller, K E Anton, A S Mulato, et al.
Journal of Medical Virology|July 27, 1999
Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapyE F Bowen, J M Cherrington, P D Lamy, et al.
The Journal of Infectious Diseases|November 17, 1998
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcomeJ M Cherrington, M D Fuller, P D Lamy, et al.
Molecular Pharmacology|August 4, 1998
Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivityM D Miller, P D Lamy, M D Fuller, et al.
Antimicrobial Agents and Chemotherapy|July 14, 1998
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapyA S Mulato, P D Lamy, M D Miller, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2001
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408M D Miller, N A Margot, P D Lamy, et al.
Antiviral Therapy|February 22, 2000
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPAM A Wainberg, M D Miller, Y Quan, et al.
Antimicrobial Agents and Chemotherapy|April 2, 1999
9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPAK K Van Rompay, J M Cherrington, M L Marthas, et al.
Journal of Virology|March 12, 1999
Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaquesK K van Rompay, P J Dailey, R P Tarara, et al.
Antimicrobial Agents and Chemotherapy|September 15, 2001
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adultsP Barditch-Crovo, S G Deeks, A Collier, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The Journal of Infectious Diseases|December 8, 1998
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitroM D Miller, K E Anton, A S Mulato, et al.
Journal of Medical Virology|July 27, 1999
Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapyE F Bowen, J M Cherrington, P D Lamy, et al.
The Journal of Infectious Diseases|November 17, 1998
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcomeJ M Cherrington, M D Fuller, P D Lamy, et al.
Molecular Pharmacology|August 4, 1998
Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivityM D Miller, P D Lamy, M D Fuller, et al.
Antimicrobial Agents and Chemotherapy|July 14, 1998
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapyA S Mulato, P D Lamy, M D Miller, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2001
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408M D Miller, N A Margot, P D Lamy, et al.
Antiviral Therapy|February 22, 2000
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPAM A Wainberg, M D Miller, Y Quan, et al.
Antimicrobial Agents and Chemotherapy|April 2, 1999
9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPAK K Van Rompay, J M Cherrington, M L Marthas, et al.
Journal of Virology|March 12, 1999
Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaquesK K van Rompay, P J Dailey, R P Tarara, et al.
Antimicrobial Agents and Chemotherapy|September 15, 2001
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adultsP Barditch-Crovo, S G Deeks, A Collier, et al.
Pageof 2